Back to Search Start Over

Data from Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

Authors :
M. Eileen Dolan
Georgia Chenevix-Trench
Anna deFazio
Beth Y. Karlan
Jenny Gross
Ignace Vergote
Evelyn Despierre
Diether Lambrechts
Jim Paul
Robert Brown
Kunle Odunsi
Matthew Grasela
Kirsten B. Moysich
Allan Jensen
Susanne K. Kjaer
Estrid Hogdall
Brooke L. Fridley
Robert A. Vierkant
Ellen L. Goode
Stuart MacGregor
Yi Lu
Nancy J. Cox
Soma Das
Yarden S. Fraiman
Peter H. O'Donnell
Shuangli Mi
Jonathan Beesley
Peixian Chen
Emily O. Kistner
Wei Zhang
Shiwei Duan
Dana Ziliak
Hae Kyung Im
Eric R. Gamazon
Sharon E. Johnatty
R. Stephanie Huang
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Purpose: Cell-based approaches were used to identify genetic markers predictive of patients' risk for poor response prior to chemotherapy.Experimental Design: We conducted genome-wide association studies (GWAS) to identify single-nucleotide polymorphisms (SNP) associated with cellular sensitivity to carboplatin through their effects on mRNA expression using International HapMap lymphoblastoid cell lines (LCL) and replicated them in additional LCLs. SNPs passing both stages of the cell-based study were tested for association with progression-free survival (PFS) in patients. Phase 1 validation was based on 377 ovarian cancer patients receiving at least four cycles of carboplatin and paclitaxel from the Australian Ovarian Cancer Study (AOCS). Positive associations were then assessed in phase 2 validation analysis of 1,326 patients from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.Results: In the initial GWAS, 342 SNPs were associated with carboplatin-induced cytotoxicity, of which 18 unique SNPs were retained after assessing their association with gene expression. One SNP (rs1649942) was replicated in an independent LCL set (Bonferroni adjusted P < 0.05). It was found to be significantly associated with decreased PFS in phase 1 AOCS patients (Pper-allele = 2 × 10−2), with a stronger effect in the subset of women with optimally debulked tumors (Pper-allele = 4 × 10−3). rs1649942 was also associated with poorer overall survival in women with optimally debulked tumors (Pper-allele = 9 × 10−3). However, this SNP was not significant in phase 2 validation analysis with patients from numerous cohorts.Conclusion: This study shows the potential of cell-based, genome-wide approaches to identify germline predictors of treatment outcome and highlights the need for extensive validation in patients to assess their clinical effect. Clin Cancer Res; 17(16); 5490–500. ©2011 AACR.

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....387a1caea131cef62cd03210cf4d7f74
Full Text :
https://doi.org/10.1158/1078-0432.c.6519360.v1